Unknown

Dataset Information

0

High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.


ABSTRACT: BACKGROUND:Tuberculosis regimens that are shorter and simpler than the current 6-month daily regimen are needed. METHODS:We randomly assigned patients with newly diagnosed, smear-positive, drug-sensitive tuberculosis to one of three regimens: a control regimen that included 2 months of ethambutol, isoniazid, rifampicin, and pyrazinamide administered daily followed by 4 months of daily isoniazid and rifampicin; a 4-month regimen in which the isoniazid in the control regimen was replaced by moxifloxacin administered daily for 2 months followed by moxifloxacin and 900 mg of rifapentine administered twice weekly for 2 months; or a 6-month regimen in which isoniazid was replaced by daily moxifloxacin for 2 months followed by one weekly dose of both moxifloxacin and 1200 mg of rifapentine for 4 months. Sputum specimens were examined on microscopy and after culture at regular intervals. The primary end point was a composite treatment failure and relapse, with noninferiority based on a margin of 6 percentage points and 90% confidence intervals. RESULTS:We enrolled a total of 827 patients from South Africa, Zimbabwe, Botswana, and Zambia; 28% of patients were coinfected with the human immunodefiency virus. In the per-protocol analysis, the proportion of patients with an unfavorable response was 4.9% in the control group, 3.2% in the 6-month group (adjusted difference from control, -1.8 percentage points; 90% confidence interval [CI], -6.1 to 2.4), and 18.2% in the 4-month group (adjusted difference from control, 13.6 percentage points; 90% CI, 8.1 to 19.1). In the modified intention-to-treat analysis these proportions were 14.4% in the control group, 13.7% in the 6-month group (adjusted difference from control, 0.4 percentage points; 90% CI, -4.7 to 5.6), and 26.9% in the 4-month group (adjusted difference from control, 13.1 percentage points; 90% CI, 6.8 to 19.4). CONCLUSIONS:The 6-month regimen that included weekly administration of high-dose rifapentine and moxifloxacin was as effective as the control regimen. The 4-month regimen was not noninferior to the control regimen. (Funded by the European and Developing Countries Clinical Trials Partnership and the Wellcome Trust; RIFAQUIN Current Controlled Trials number, ISRCTN44153044.).

SUBMITTER: Jindani A 

PROVIDER: S-EPMC4233406 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>Tuberculosis regimens that are shorter and simpler than the current 6-month daily regimen are needed.<h4>Methods</h4>We randomly assigned patients with newly diagnosed, smear-positive, drug-sensitive tuberculosis to one of three regimens: a control regimen that included 2 months of ethambutol, isoniazid, rifampicin, and pyrazinamide administered daily followed by 4 months of daily isoniazid and rifampicin; a 4-month regimen in which the isoniazid in the control regimen was rep  ...[more]

Similar Datasets

| S-EPMC7307310 | biostudies-literature
| S-EPMC8282329 | biostudies-literature
| S-EPMC4861335 | biostudies-literature
| S-EPMC2718441 | biostudies-other
| S-EPMC5545752 | biostudies-literature
| S-EPMC5159618 | biostudies-literature
| S-EPMC7827815 | biostudies-literature
| S-EPMC5709238 | biostudies-literature
| S-EPMC6535519 | biostudies-literature
| S-EPMC4136068 | biostudies-literature